Skip to content

CapEx at other companies

AbbVie logo
AbbVieABBV
$265M+12.8%
Bausch + Lomb logo
Bausch + LombBLCO
$100M-9.1%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$4.66M+141%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$942K+249%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$230.6M+0.6%
Warby Parker logo
Warby ParkerWRBY
$16.14M-0.1%

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s capex?
Tarsus Pharmaceuticals, Inc. (TARS) reported capex of $5.82M in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s capex changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s capex increased by 886.1% year-over-year, from $590K to $5.82M.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s capex?
Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s capex has grown at a 102.5% compound annual growth rate (CAGR), from $586K to $9.86M.
What does capex mean?
Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.